Insider Analysis From Anand & Anand, New Dehli: What’s The Secret Behind Your Medicine? Exclusivity Or Protection Of Clinical Trial Data In India (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
By M. S. Bharath, Partner, Anand & Anand, New Dehli, India
You may also be interested in...
Indian Pharmaceutical Alliance Questions Data Exclusivity Survey; Says Transparency Lacking
NEW DELHI - The Indian Pharmaceutical Alliance - an association representing 12 leading Indian pharmaceutical companies - has raised strong opposition to a survey on data exclusivity being conducted by the New Delhi-based law firm Anand and Anand
Indian Pharmaceutical Alliance Questions Data Exclusivity Survey; Says Transparency Lacking
NEW DELHI - The Indian Pharmaceutical Alliance - an association representing 12 leading Indian pharmaceutical companies - has raised strong opposition to a survey on data exclusivity being conducted by the New Delhi-based law firm Anand and Anand
Johnson & Johnson Establishes Beijing Diabetes Institute
Johnson & Johnson has established its diabetes institute in Beijing, one of the company's first batch of four non-commercial institutes worldwide. The facility provides a free training platform for China's diabetes educators and managers. Over the next three years, the institute will work with the Ministry of Health to bring together local and overseas specialists and academics in the field to explore new standardized models with Chinese characteristics for managing the disease. Analysts believe the diabetes management model will allow China to maximize its health care resources to derive the most social benefits, especially previously idle community resources. (Click here for more - Chinese Language)